Galectin-3 in NAFLD: Therapeutic Target or Noncausal Biomarker?
Open Access
- 21 May 2021
- journal article
- editorial
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (9) , e3773-e3774
Abstract
Raymond E Soccio, MD, PhD; Galectin-3 in NAFLD: therapeutic target or non-causal biomarker?, The Journal of Clinical Endocrinology & Metabolism, , dgab363, httpKeywords
This publication has 4 references indexed in Scilit:
- Immunopathology of galectin-3: an increasingly promising target in COVID-19F1000Research, 2020
- Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various DiseasesBiomolecules, 2020
- Galectin-3: One Molecule for an Alphabet of Diseases, from A to ZInternational Journal of Molecular Sciences, 2018
- Using human genetics to discover new therapeutic targets for plasma lipidsJournal of Internal Medicine, 2016